Orient Pharma Co., Ltd. (TPEX:4166)

Market Cap	5.35B -3.7%
Revenue (ttm)	1.52B +20.1%
Net Income	235.25M +195.1%
EPS	0.98 +174.5%
Shares Out	243.04M
PE Ratio	22.49
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	139,444
Open	23.25
Previous Close	22.70
Day's Range	22.00 - 23.25
52-Week Range	22.00 - 29.60
Beta	0.07
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 20, 2026

About Orient Pharma

Orient Pharma Co., Ltd. engages in the development of new drugs in Taiwan and internationally. It offers cardiovascular drugs, such as Pitator and Tonvasca for lipid suppression, as well as Zulitor, a lipid lowering drug; psychotropic drugs, including Trokendi XR extended, Methydur, and powder and solvent for prolonged-release suspension for injection. The company was founded in 2008 and is based in Taipei, Taiwan.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2008
• Employees: 173
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4166

Financial Performance

In 2025, Orient Pharma's revenue was 1.40 billion, an increase of 14.52% compared to the previous year's 1.22 billion. Earnings were 208.44 million, an increase of 94.12%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 6, 2026

Data Sources Report a data error